Utilize nationally representative data to project the number of cancer patients in the US who are being treated with individual drugs and/or regimens.
Influence Drug Adoption and Utilization
A new age of data is upon us and projecting drug adoption and utilization for the oncology market requires a sophisticated approach that accounts for the complexities and variations in cancer care. Life sciences companies must now account for multiple characteristics and sites of care to accurately represent and project national trends.
Our unique projection methodology starts with a holistic view of actual longitudinal patient and physician data, such as unique prescribing patterns of the physician and size of the patient population your drug is being used to treat. Through that, we apply parameters such as age, gender, disease, stage, biomarkers and line of therapy to allow insights into the current patterns of national drug usage.
Applying a more precise, tumor-based approach and the inclusion of certain attributes, we can better address smaller tumor markets that affect the adoption or utilization of a drug based on patient or physician characteristics. Applying a greater level of statistical estimation, we can project within an individual condition across and within subpopulations with a precise level of assessment.
Use timely insights based on new projection methodologies to accurately evaluate market opportunities. With our next generation drug utilization and profiling analytics solution, PrecisionIQ, you can now access timely, secure longitudinal oncology treatment information from pre-launch through the commercial life of your drug.